InVivo Therapeutics released its 2018 third quarter financial results.
Here are four highlights:
1. Operating expenses for the third quarter were $2.1 million, compared to $6.3 million in the third quarter of 2017.
2. InVivo anticipates it will continue to maintain its current cash burn rate of less than $1 million per month, including expenses related to clinical studies.
3. The company reported a $3.2 million net loss for the quarter, compared to the $9.4 million net loss in the third quarter of 2017.
4. InVivo ended the quarter with $19.7 million of cash and cash equivalents.
To view the full financial report, click here.